ResearcherWestlake UniversityActive in the last 2 years
Dongchao Xu
Matched on ORCID iD 0000-0002-1608-8866; OpenAlex author ID A5032449956. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 7
- Palmaturbine Inhibits Pancreatic Ductal Adenocarcinoma by Suppressing the JAK2/STAT3 Signaling Pathway. Co-author DOI 10.3390/ijms27041707↗
- Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated degradation. Co-author DOI 10.1016/j.phymed.2025.157245↗
- Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and trigger endoplasmic reticulum stress. Co-author DOI 10.1016/j.intimp.2024.113497↗
- Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis. Co-author DOI 10.1016/j.bcp.2023.115810↗
- Linderalactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signaling Pathway. Co-author DOI 10.1155/2022/8675096↗
- Cucurbitacin I inhibits the proliferation of pancreatic cancer through the JAK2/STAT3 signalling pathway in vivo and in vitro. Co-author DOI 10.7150/jca.65875↗
- The MYEOV-MYC association promotes oncogenic miR-17/93-5p expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-021-04387-z↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hongzhang Shen · 7 shared papers, 2021–2026 · strength 1.62
- Paper Palmaturbine Inhibits Pancreatic Ductal Adenocarcinoma by Suppressing the JAK2/STAT3 Signaling Pathway. DOI 10.3390/ijms27041707↗
- Paper Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated … DOI 10.1016/j.phymed.2025.157245↗
- Paper Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and tr… DOI 10.1016/j.intimp.2024.113497↗
- Xiaofeng Zhang · 4 shared papers, 2022–2025 · strength 0.87
- Paper Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated … DOI 10.1016/j.phymed.2025.157245↗
- Paper Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and tr… DOI 10.1016/j.intimp.2024.113497↗
- Paper Cucurbitacin I inhibits the proliferation of pancreatic cancer through the JAK2/STAT3 signalling pathway in vivo and in… DOI 10.7150/jca.65875↗
- Mengyao Tian · 3 shared papers, 2022–2024 · strength 0.59
- Paper Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and tr… DOI 10.1016/j.intimp.2024.113497↗
- Paper Cucurbitacin I inhibits the proliferation of pancreatic cancer through the JAK2/STAT3 signalling pathway in vivo and in… DOI 10.7150/jca.65875↗
- Paper Linderalactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signali… DOI 10.1155/2022/8675096↗
- Qiang Liu · 3 shared papers, 2022–2024 · strength 0.58
- Paper Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and tr… DOI 10.1016/j.intimp.2024.113497↗
- Paper Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis. DOI 10.1016/j.bcp.2023.115810↗
- Paper Linderalactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signali… DOI 10.1155/2022/8675096↗
- Yulian Wu · 1 shared paper, 2026 · strength 0.43
- Meidan Ying · 1 shared paper, 2023 · strength 0.19
- Juanjuan Zhu · 1 shared paper, 2021 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.